慢性乙型肝炎患者治疗前后的血清维生素D水平。

StephenW

Infect Disord Drug Targets. 2019 Nov 11. doi: 10.2174/1871526519666191112112903. [Epub ahead of print]
Serum Vitamin D Levels in Chronic Hepatitis B Patients Before and During Treatment.
Mohamed AA1, Abdo S2, Said E3, Agawy WE4, Awad P5, Mohamed Ghanem AI6, Khattab RA7, El-Damasy DA8, Elkadeem M9, Abd-Elsalam S9.
Author information

1
    Biochemistry Department, National Hepatology and Tropical medicine, Cairo, Egypt.
2
    Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty of Medicine banha university, Egypt.
3
    Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty of Medicine banha university , Egypt.
4
    Hepatology , Gastroenterology and Infectious Diseases Department ,Faculty of Medicine Portsaid University, Egypt.
5
    Gastroenterology and Hepatology Department, Kobry el kobba Military Hospital, Egypt.
6
    Clinical Pathology Department , National Institute of Diabetics and Endocrinology , Egypt.
7
    Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
8
    Microbiology Department , Faculty of Pharmacy, Egyptian Russian University , Egypt.
9
    Tropical Medicine Department, Tanta University, Egypt.

Abstract
BACKGROUND & AIMS:

Hepatitis B is a potentially life-threatening liver infection and it is a major global health problem. Over the past decade, numerous studies have reported that patients with CLD, especially HCV-positive and HBV-positive patients, have decreased 25(OH) D levels. The current study was designed to assess the serum levels of vitamin D [25(OH) D3] in chronic hepatitis B patients, before and during treatment with antiviral therapy.
METHODS:

It was a prospective study in which 80 subjects were enrolled between December 2017 and June 2018. A total of 50 treatment-naïve chronic HBV patients and 30 healthy subjects were recruited. The studied cases received treatment in the form of Lamivudine 100 mg tablet, once daily. Full routine laboratory investigations, HBV DNA measurement by real time PCR; once before initiation of antiviral treatment and again at least 6 months later, serum vitamin D level [25(OH)D3; assessed twice, once before initiation of antiviral treatment and again at least 6 months later; were done for all the patients enrolled in the study.
RESULTS:

The studied cases showed a significantly low mean serum Vitamin D level when assessed before treatment (21.6 ± 5.8 ng/ml), compared to the level after 6 ms of treatment (31.1 ± 7.3 ng/ml) that was comparable to that of the control group (33.4 ± 5 ng/ml).
CONCLUSION:

The present study highlights the impact of antiviral therapy on vitamin D deficiency in CHB patients, where an effective therapy improves vitamin D levels. Meanwhile it is recommended to study the impact of vitamin D replacement and correction on the disease progression or regression.

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
KEYWORDS:

Antiviral therapy; Chronic liver disease; Hepatitis B; Lamivudine.; Vitamin D levels

PMID:
    31721718
DOI:
    10.2174/1871526519666191112112903

StephenW

感染Disord药物目标。 2019年11月11日.doi：10.2174 / 1871526519666191112112903。 [Epub提前发布]
慢性乙型肝炎患者治疗前后的血清维生素D水平。
Mohamed AA1，Abdo S2，Said E3，Agawy WE4，Awad P5，Mohamed Ghanem AI6，Khattab RA7，El-Damasy DA8，Elkadeem M9，Abd-Elsalam S9。
作者信息

1个
    埃及开罗国家肝病和热带医学生物化学系。
2
    埃及班哈大学医学院肝病，胃肠病学和传染病系。
3
    埃及班哈大学医学院肝病，胃肠病学和传染病系。
4
    埃及朴赛德大学医学院肝病，胃肠病学和传染病系。
5
    埃及Kobry el kobba军事医院消化内科和肝病科。
6
    埃及国家糖尿病与内分泌研究所临床病理学系。
7
    开罗大学药学院微生物学和免疫学系，埃及开罗。
8
    埃及埃及俄罗斯大学药学院微生物学系。
9
    埃及坦塔大学热带医学系。

抽象
背景与目的：

乙型肝炎是可能威胁生命的肝脏感染，是全球主要的健康问题。在过去的十年中，许多研究报告称CLD患者，特别是HCV阳性和HBV阳性的患者，其25（OH）D水平降低了。当前的研究旨在评估慢性乙型肝炎患者在抗病毒治疗之前和期间的维生素D [25（OH）D3]血清水平。
方法：

这是一项前瞻性研究，在2017年12月至2018年6月之间招募了80名受试者。共招募了50名未接受过治疗的慢性HBV患者和30名健康受试者。研究的病例每天接受一次拉米夫定100 mg片剂的治疗。全面的常规实验室检查，通过实时PCR测量HBV DNA；一次开始抗病毒治疗之前，至少在6个月后再次，血清维生素D水平[25（OH）D3;在开始抗病毒治疗之前进行两次评估，至少在六个月后进行评估；对所有参与研究的患者进行了检查。
结果：

研究病例显示，治疗前评估的平均血清维生素D水平较低（21.6±5.8 ng / ml），而治疗后6毫秒（31.1±7.3 ng / ml）则与对照组相当。组（33.4±5ng / ml）。
结论：

本研究强调了抗病毒治疗对CHB患者维生素D缺乏症的影响，其中有效的治疗可改善维生素D水平。同时，建议研究维生素D的替代和纠正对疾病进展或消退的影响。

版权所有©Bentham Science Publishers；保留所有权利。如有任何疑问，请发送电子邮件至[email protected]。
关键字：

抗病毒治疗；慢性肝病乙型肝炎；拉米夫定。维生素D水平

PMID：
    31721718
DOI：
    10.2174 / 1871526519666191112112903

neilhbver

又一片维生素d相关的研究，不过我发现澳洲的复合维生素品牌各种维生素普遍含量较低，大家可以买美国的对比一下